BACKGROUND: The reported decreasing benefit with increasing age from concurrent chemoradiotherapy in head and neck cancer patients prompted this retrospective review. METHODS: Two courses of cisplatin-based concurrent chemoradiotherapy were given to fit patients ≥70 years with locoregionally advanced cancers. Clinical characteristics, treatment, and outcomes were compared with those for an identically treated cohort <70 years. RESULTS: There were 44 patients ≥70 and 137 patients <70 years. Clinical characteristics, treatment and toxicities were similar except that the elderly were less likely to receive both chemotherapy courses, experienced more myelosuppression, required more unplanned hospitalization, and were feeding-tube dependent longer. Projected 5-year disease-specific survival (71% vs 74%) and freedom from recurrence (69% v. 71%) were nearly identical. CONCLUSIONS: Although these selected elderly patients experienced greater myelosuppression and supportive care requirements, outcomes were the same as in younger patients. Age alone should not be considered a contraindication to aggressive chemoradiotherapy for this disease.
BACKGROUND: The reported decreasing benefit with increasing age from concurrent chemoradiotherapy in head and neck cancerpatients prompted this retrospective review. METHODS: Two courses of cisplatin-based concurrent chemoradiotherapy were given to fit patients ≥70 years with locoregionally advanced cancers. Clinical characteristics, treatment, and outcomes were compared with those for an identically treated cohort <70 years. RESULTS: There were 44 patients ≥70 and 137 patients <70 years. Clinical characteristics, treatment and toxicities were similar except that the elderly were less likely to receive both chemotherapy courses, experienced more myelosuppression, required more unplanned hospitalization, and were feeding-tube dependent longer. Projected 5-year disease-specific survival (71% vs 74%) and freedom from recurrence (69% v. 71%) were nearly identical. CONCLUSIONS: Although these selected elderly patients experienced greater myelosuppression and supportive care requirements, outcomes were the same as in younger patients. Age alone should not be considered a contraindication to aggressive chemoradiotherapy for this disease.
Authors: Caitriona B O'Neill; Shrujal S Baxi; Coral L Atoria; James P O'Neill; Martin C Henman; Eric J Sherman; Nancy Y Lee; David G Pfister; Elena B Elkin Journal: Cancer Date: 2015-02-27 Impact factor: 6.860
Authors: Zachary S Zumsteg; Benjamin H Lok; Allen S Ho; Esther Drill; Zhigang Zhang; Nadeem Riaz; Stephen L Shiao; Jennifer Ma; Sean M McBride; C Jillian Tsai; Shrujal S Baxi; Eric J Sherman; Nancy Y Lee Journal: Cancer Date: 2016-12-16 Impact factor: 6.860
Authors: Noam A VanderWalde; Anne-Marie Meyer; Huan Liu; Seth D Tyree; Leah L Zullig; William R Carpenter; Carol D Shores; Mark C Weissler; David N Hayes; Mary Fleming; Bhishamjit S Chera Journal: J Geriatr Oncol Date: 2013-07 Impact factor: 3.599
Authors: Sheela Hanasoge; Kelly R Magliocca; Jeffrey M Switchenko; Nabil F Saba; J Trad Wadsworth; Mark W El-Deiry; Dong M Shin; Fadlo Khuri; Jonathan J Beitler; Kristin A Higgins Journal: Head Neck Date: 2015-07-30 Impact factor: 3.147
Authors: M Di Genesio Pagliuca; C Perotti; G Apicella; A Galla; M Guffi; M Paolini; L Donis; V Amisano; S Torrente; I Manfredda; M Krengli Journal: Clin Transl Oncol Date: 2015-09-14 Impact factor: 3.405
Authors: Shrujal S Baxi; Caitriona O'Neill; Eric J Sherman; Coral L Atoria; Nancy Y Lee; David G Pfister; Elena B Elkin Journal: Head Neck Date: 2015-06-26 Impact factor: 3.147
Authors: Caitriona B O'Neill; James P O'Neill; Coral L Atoria; Shrujal S Baxi; Martin C Henman; Ian Ganly; Elena B Elkin Journal: Laryngoscope Date: 2014-10-04 Impact factor: 3.325
Authors: Ronald J Maggiore; Emily K Curran; Mary Ellyn Witt; Daniel J Haraf; Everett E Vokes; Ezra E W Cohen Journal: J Geriatr Oncol Date: 2013-06-10 Impact factor: 3.599